Clinical Trial on Methylprednisolone - Clinical Trials Registry

Study Overview

Status

Completed

Conditions

Healthy

Intervention / Treatment

Drug: Methylprednisolone

Study Type

Interventional

Enrollment

20

Phase

Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Denmark
- - Holstebro, Denmark
    - Department of Medicine, Holstebro Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

(1) Genders; both mal and female
(2) Age; 18- 65 years old
(3) BMI; below 30
(4) Females had to bee in oral contraceptive treatment

Exclusion Criteria:

(1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine organs
(2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose)
(3) Albuminuria or glucosuria
(4) Cancer
(5) Arterial hypertension
(6) Alcohol abuse
(7) Use of tobacco
(8) Medical treatment, except oral contraceptives
(9) Pregnancy or breast feeding
(10) Medicine abuse
(11) Donation of blood less than 1 month before the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Allocation: Randomized
Interventional Model: Crossover Assignment
Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure
u-AQP-2
FeNa+

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Regional Hospital Holstebro

Investigators

Study Chair: Erling B Pedersen, Professor, Holstebro Hospital, 7500 Holstebro, Denmark
Principal Investigator: Thomas G Knudsen, MD, Holstebro Sygehus

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2005

Primary Completion (Actual)

February 1, 2007

Study Completion (Actual)

February 1, 2007

Study Registration Dates

First Submitted

January 23, 2006

First Submitted That Met QC Criteria